Get started
Author

Jianbin Zhu

ORCID: 0000-0002-4716-6628
Observed ORCID: 0000-0002-4716-6628
OpenAlex ID: A5121393261
Enhanced CT-based deep learning radiomics and biological correlations for predicting immunotherapy efficacy in advanced non-small cell lung cancer
2026 · Jianbin Zhu, Huaxian Shi, et al. · Translational Cancer Research · 2
Any regression of tumor (ART) to discriminate improvement in overall survival (OS) in patients with metastatic urothelial carcinoma (mUC) receiving PD1/L1 inhibitors who exhibit stable disease (SD) by RECIST1.1.
2026 · Bakr Alhayek, Susmita Potti, et al. · Journal of Clinical Oncology
Early peripheral blood neutrophil/lymphocyte ratio (NLR) dynamics to predict primary refractory disease in metastatic urothelial carcinoma (mUC) patients receiving PD1/L1 inhibitors.
2026 · Bakr Alhayek, Susmita Potti, et al. · Journal of Clinical Oncology
Comprehensive plasma metabolomic profiling of metastatic urothelial carcinoma (mUC) pre- and post-immune checkpoint inhibitor (ICI) or platinum-based chemotherapy (PBC).
2026 · Susmita Potti, Praful Ravi, et al. · Journal of Clinical Oncology
A phase II study of zanzalintinib for patients with advanced urothelial carcinoma following prior therapy.
2026 · Jason Robert Brown, Andrea B. Apolo, et al. · Journal of Clinical Oncology
Sequential flotufolastat-F18 PSMA-PET scans to enhance detection of prostate cancer in patients with early PSA recurrence following radical prostatectomy.
2026 · Rajesh Sehgal, Marcio Moschovas, et al. · Journal of Clinical Oncology
Machine Learning–Driven Risk Stratification and Adjuvant Treatment Guidance in Oral Cavity Cancer
2026 · Andrea Costantino, Nir Tsur, et al. · JCO Precision Oncology
Integrating clinical features and the CT-based intratumoral heterogeneity to predict immunotherapy response in NSCLC
2025 · Jianbin Zhu, Zhuofeng Liang, et al. · Asian Journal of Surgery
Works count: 8
Citation count: 2
H-index: 1
I10-index:
Year
Topic
Type